Seraxis, Inc.
Seraxis is a private biotechnology company launched in 2013, located in Germantown, Maryland. Its mission is to develop practical and potent cell replacement therapies for insulin-dependent diabetes. The company has developed novel cell and immune-evasion technologies to reverse diabetes in animal models and is working to advance these therapies to the clinic. Seraxis is engaged in developing therapies such as pancreatic organoids and islet cell tech, with a focus on stem cell-derived treatments for type 1 diabetes. It has received various grants, completed GMP quality system audits, and is involved in clinical studies and collaborations to bring its therapies into clinical practice. The company is also active in publishing research and presenting at conferences.
Industries
Nr. of Employees
small (1-50)
Products
SR-02 clinical candidate (replacement islets)
A clinical-stage cell therapy candidate intended as a replacement islet product for treatment of Type 1 diabetes; advanced to an FDA IND allowance for a clinical study.
Pancreatic organoid / pancreatic cluster platform (preclinical)
Preclinical platform composed of synthetic replacement endocrine clusters or pancreatic organoids developed to replace missing islets and control blood glucose in animal models.
SR-02 clinical candidate (replacement islets)
A clinical-stage cell therapy candidate intended as a replacement islet product for treatment of Type 1 diabetes; advanced to an FDA IND allowance for a clinical study.
Pancreatic organoid / pancreatic cluster platform (preclinical)
Preclinical platform composed of synthetic replacement endocrine clusters or pancreatic organoids developed to replace missing islets and control blood glucose in animal models.
Services
Strategic scientific collaborations and licensing
Engagements with external organizations for research collaborations, licensing of technologies, and co-development partnerships to advance cell replacement therapies.
Strategic scientific collaborations and licensing
Engagements with external organizations for research collaborations, licensing of technologies, and co-development partnerships to advance cell replacement therapies.
Expertise Areas
- Stem cell differentiation and beta-cell generation
- Pancreatic organoid and cluster development
- Preclinical efficacy testing in diabetes models
- Immuno-engineering for cell transplantation
Key Technologies
- Pluripotent stem cell differentiation
- Pancreatic organoids / cluster engineering
- Cell transplantation / islet replacement
- Immune-evasion engineering